Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis
Supernus offers transitional revaluation potential as CNS growth franchises scale, but Qelbree patent defense and Onapgo execution will determine whether the discount closes.
Overview
Supernus Pharmaceuticals is a U.S.-focused CNS specialty biopharma transitioning from legacy anti-epilepsy dependence to proprietary growth assets in ADHD, Parkinson’s disease, postpartum depression, and epilepsy. Qelbree, Gocovri, Zurzuvae, and Onapgo provide differentiated commercial opportunities through non-stimulant ADHD treatment, Parkinson’s motor-fluctuation therapies, and neuropsychiatry expansion. The company benefits from targeted specialty sales, strong patent estates, and a debt-free balance sheet, but must overcome GAAP losses, generic litigation, integration costs, and execution risks.